Treatment with hyperglycemia and chronic insulin or normoglycemia and the pharmacological OGA inhibitor, PUGNAc, result in the global elevation of O-GlcNAc modified nucleocytosolic proteins and insulin resistance in rodent adipocytes [19,57]. The gene discussed is INS; the disease is Hyperglycemia.